Enanta Pharmaceuticals to Participate in December Investor Conferences

Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ:ENTA) announced participation in two virtual investor conferences in December 2021. Jay R. Luly, President and CEO, will speak at the Evercore ISI HealthCONx Conference on December 1, 2021, at 10:30 a.m. ET, and will also present at the Piper Sandler Healthcare Conference on December 2, 2021. A pre-recorded chat will be available to attendees on November 29, 2021. Webcasts will be accessible on Enanta's website and archived for 14 days.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two virtual investor conferences in December:

• Evercore ISI 4^th Annual HealthCONx Conference, December 1, 2021 with a fireside chat at 10:30 a.m. ET.
• Piper Sandler 33^rd Annual Healthcare Conference, December 2, 2021. Company pre-recorded fireside chat will become available to registered conference attendees on Monday, November 29, 2021 at 10:00 a.m. ET.

A webcast of the each event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. Replays of the webcasts will be available following the presentations and will be archived for at least 14 days.

About Enanta
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts have produced clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and SARS-CoV-2 (COVID-19). Enanta is also conducting research in human metapneumovirus (hMPV).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211119005117/en/

Investor

Jennifer Viera

617-744-3848

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

What conferences will Enanta Pharmaceuticals participate in December 2021?

Enanta Pharmaceuticals will participate in the Evercore ISI HealthCONx Conference on December 1 and the Piper Sandler Healthcare Conference on December 2, 2021.

What time will Jay R. Luly's presentation be at the Evercore ISI HealthCONx Conference?

Jay R. Luly will participate in a fireside chat at the Evercore ISI HealthCONx Conference at 10:30 a.m. ET on December 1, 2021.

When will the pre-recorded chat for the Piper Sandler Healthcare Conference be available?

The pre-recorded fireside chat for the Piper Sandler Healthcare Conference will be available to registered attendees on November 29, 2021, at 10:00 a.m. ET.

How can I access the webcasts of Enanta Pharmaceuticals' presentations?

Webcasts of Enanta's presentations will be accessible on the 'Events and Presentations' section of their website and archived for at least 14 days.

What are Enanta Pharmaceuticals' main areas of research?

Enanta Pharmaceuticals focuses on developing small molecule drugs for viral infections and liver diseases, including targets like RSV, HBV, and SARS-CoV-2.